BioPorto A/S : Increase of the share capital through a cash issue, private placement

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.

Today, BioPorto A/S initiates a private placement of up to 11,724,750 new shares to selected institutional and financial investors. The offering of shares will be made at market price without pre-emptive rights for existing shareholders.

Today, The Board of BioPorto A/S (BioPorto) has decided to carry out a cash issue, private placement, of up to 11,724,750 new shares at market price.

Use of proceeds

During the summer of 2015, BioPorto's management has uncovered and evaluated the possible strategies for market entry for NGAL in the USA. This has resulted in a strategy, which is targeted and extends beyond the original plans. Therefore, BioPorto is completing a capital increase, of which part of the net proceeds are expected to be used for establishing a business platform in the USA, which will include BioPorto's own US sales and support organization in charge of the commercialization of The NGAL Test™ when FDA approval is expectedly achieved in early 2016. Part of the proceeds are expected to be used to complete the development and marketing of the new products gRAD and immunodeficiency tests as well as other projects.

The offer

The capital increase takes the form of a cash issue for a limited group of institutional and financial investors without a pre-emptive right for the Company's previous shareholders according to the authorization stipulated in Article 16b of BioPorto's Company Articles.

The offering is up to 11,724,750 new shares at DKK 1 each, equivalent to 9,9% of BioPorto's registered share capital before the capital increase. The Board has received binding advance commitments to the subscription of the full number of shares. The subscription price is DKK 2.40 and is calculated as the weighted average price of the share at Nasdaq Copenhagen over the past ten trading days. The expected total proceeds from the share issue will amount to DKK 28,139,400 at a full subscription.

The same rights apply to newly subscribed shares as to the existing shares. The new shares are issued to the holders through VP SECURITIES A/S, and may be registered in BioPorto's register of shareholders. The rights relating to the new shares, including voting rights and dividend rights, will apply from the time when the capital increase is registered with the Danish Business Authority.

Expected timetable for the capital increase

The subscription period starts today and ends on September 1, 2015. The Board of Directors may choose to complete the issue prior to this date.

The capital increase will be registered with the Danish Business Authority as soon as the subscription amount is fully paid, expectedly Friday, September 4, 2015.

The new shares will be issued in a temporary unlisted ISIN code and is expected to be admitted to trading and official listing on Nasdaq Copenhagen under the existing ISIN code for BioPorto's shares by September 2015.

For further information, please contact:

Peter Mørch Eriksen, CEO

Telephone +45 4529 0000, e-mailinvestor@bioporto.com

About BioPorto

BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Our pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury. We sell our products in more than 80 countries through diverse sales channels and partners. BioPorto has its headquarters in Copenhagen, Denmark and is listed on the Nasdaq Copenhagen stock exchange.

This announcement contains forward-looking statements on BioPorto's future financial developments and financial results as well as other statements that are not historical facts and that may prove to be incorrect. Prospective investors should seek professional investment advice and examine relevant risks and legal aspects, including tax aspects, which could be relevant in connection with an acquisition of the shares.

The information contained herein is not for publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. These written materials do not constitute an offer of securities for sale in any jurisdiction including the United States, nor may the securities be offered or sold in the United States absent registration or an exemption from registration as provided in the U.S. Securities Act of 1933, as amended, and the rules and regulations thereunder. There is no intention to register any portion of the offering in the United States or to conduct a public offering of securities in the United States.

The issue and sale of securities in the offering are subject to specific legal or regulatory restrictions in certain jurisdictions. BioPorto and its advisers and/or agents assumes no responsibility in the event there is a violation by any person of such restrictions.

The information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction.

This announcement is only addressed to and directed at persons in member states of the European Economic Area (the "EEA"), who are "Qualified Investors" within the meaning of Article 2(1)(e) of the Prospectus Directive. The securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with Qualified Investors. This announcement should not be acted upon or relied upon in any member state of the EEA by persons who are not Qualified Investors. For the purposes of this announcement, the expression "Prospectus Directive" means Directive 2003/71/EC as amended and includes any relevant implementing measure in each Relevant Member State. This announcement is an advertisement for the purposes of applicable measures implementing the Prospectus Directive.

distributed by